Systemic delivery of peptides and proteins across absorptive mucosae

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 13, Issue 1-2, 1996, Pages 85-184

  Sayani, Amyn P ^a   Chien, Yie W ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

buccal; calcitonin; enkephalin; enzyme inhibitors; GnRH; insulin; nasal; peptides; permeation enhancers; proteins; pulmonary; rectal; transmucosal delivery; vaginal

Indexed keywords

ACTINONIN; BESTATIN; BILE SALT; BOROLEUCINE; BUSERELIN; CALCITONIN; CAMOSTAT; CAPTOPRIL; CGP 38560; CHELATING AGENT; CYCLODEXTRIN DERIVATIVE; EDETIC ACID; ENZYME INHIBITOR; GONADORELIN; GONADORELIN DERIVATIVE; INSULIN; LEUCINE ENKEPHALIN; LEUPEPTIN; LEUPRORELIN; MEMBRANE METALLOENDOPEPTIDASE; NAFARELIN; PEPSTATIN; PEPTIDE; PHOSPHINIC ACID DERIVATIVE; PROINSULIN; PROTEIN; PUROMYCIN; SALCATONIN; SURFACTANT; UNINDEXED DRUG;

CELL MEMBRANE PERMEABILITY; CHEEK MUCOSA; DRUG DEGRADATION; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG UPTAKE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; NONHUMAN; NOSE MUCOSA; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION; RECTUM MUCOSA; RESPIRATORY EPITHELIUM; REVIEW; VAGINA MUCOSA;

ABSORPTION; AMINO ACID SEQUENCE; ANIMALS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; LUNG; MOUTH MUCOSA; NASAL MUCOSA; PEPTIDES; RECOMBINANT PROTEINS; VAGINA;

EID: 0029757133     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (323)

1. Collins, L. M. C. and Dawes, C., The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa, J. Dent. Res., 66, 1300, 1987.
2. Jarrett, A., The structure of the oral mucosa, in The Physiology and Pathophysiology of the Skin, 6, Jarrett, A., Ed., Academic Press, London, England, 1871, 1980.
3. Wertz, P. W., Swartzendruber, D. C., and Squier, C. A., Regional variation in the structure and permeability of oral mucosa and skin, Adv. Drug Del. Rev., 12, 1, 1993.
4. Squier, C. A., Permeability of the oral mucosa, Crit. Rev. Oral Biol. Med., 2, 13, 1991.
5. Garren, K. W. and Repta, A. J., Buccal drug absorption. II. In vitro diffusion across hamster cheek pouch, J. Pharm. Sci., 2, 160, 1989.
6. Pimlott, S. J. and Addy, M., Evaluation of a method to study the uptake of prednisolone sodium phosphate from different oral mucosal sites, Oral Surg. Oral Med. Oral Path., 60, 35, 1985.
7. Reid, C. O., Hardcastle, J., and Smith, C. J., A comparison of some of the permeability characteristics of intact and tape-stripped hamster cheek pouches in vitro, J. Dent. Res., 65, 673, 1986.
8. Merkle, H. P., Anders, R., and Wermerskirchen, A., Buccal routes of peptide and protein drug delivery, in Peptide and Protein Drug Delivery, Lee, V. H. L., Ed., Marcel Dekker, New York, 545, 1992.
9. de Vries, M. E., Brodde, H. E., Verhoef, J. C., and Junginger, H. E., Development in buccal drug delivery, Crit. Rev. Ther. Drug Carrier Sys., 8, 271, 1991.
10. Curatolo, W., The lipoidal permeability barriers of the skin and alimentary tract, Pharm. Res., 4, 271, 1987.
11. Wertz, P. W., Kremer, M., and Squier, C. A., Comparison of lipids from epidermal and palatal stratum corneum, J. Invest. Dermatol., 98, 375, 1992.
12. Squier, C. A. and Nanny, D., Measurement of blood flow in the oral mucosa and skin of Rhesus monkey using radiolabelled microspheres, Arch. Oral Biol., 30, 313, 1985.
13. Ho, N. F. H., Barsuhn, P. S., Burton, P. S., and Merkle, H. P., Mechanistic insights to buccal delivery of protemaceous substances, Adv. Drug Del. Rev., 8, 197, 1992.
14. Weiss, L., Histology. Cell and Tissue Biology, Elsevier Biochem, Amsterdam, 765, 1983.
15. Chauncey, H. H., Salivary enzymes, J. Am. Dental Assoc., 63, 360, 1961.
16. Lindquist, L. and Augustinsson, K. B., Esterases in human saliva, Enzyme, 20, 277, 1975.
17. Chien, Y. W. and Chang, S.-F., Intranasal drug delivery for systemic medications, Crit. Rev. Ther. Drug Carrier Sys., 4, 67, 1987.
18. Chien, Y. W., Su, K. S. E., and Chang S.-F., Nasal Systemic Drug Delivery, Marcel Dekker, New York, 1989.
19. Su, K. S. E., Nasal route of peptide and protein drug delivery, in Peptide and Protein Drug Delivery, Lee, V. H. L., Ed., Marcel Dekker, New York, 1992.
20. Edman, P. and Bjork, E., (D) Routes of delivery: Case studies. (1) Nasal delivery of peptide drugs, Adv. Drug Del. Rev., 8, 165, 1992.
21. Proctor, D. F., The Upper Airways. I. Nasal physiology and defense of the lungs, Am. Rev. Respir. Dis., 115, 97, 1977.
22. Maron, Z., Shelhamer, J., and Kaliner, M., Nasal mucus secretion, Ear Nose Throat J., 63, 36, 1984.
23. Balin, B. J., Broadwell, R. D., Saleman, M., and Kalliny, E. L., Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey, J. Comp. Neurol., 251, 260, 1986.
24. Gopinath, P. G., Gopinath, G., and Anand Kuniar, T. C., Target site of intranasally sprayed substances and their transport across the nasal mucosa: A new insight into the intranasal route of drug delivery, Curr. Ther. Res., 23, 596, 1978.
25. Geurkink, N., Nasal anatomy, physiology, and function, J. Allergy Clin. Immunol., 72, 123, 1983.
26. Taylor, M., The origins and functions of nasal mucus, Laryngoscope, 84, 612, 1974.
27. Lorin, M. I., Gaerlan, P. F., and Mandel, I. D., Qualitative composition of nasal secretions in normal subjects, J. Lab. Clin. Med., 80, 725, 1972.
28. Rosen, R. D., Alford, R. H., Butler, W. T., and Vannier, W. E., The separation and characterization of proteins intrinsic to nasal secretions, Eur. J. Immunol., 97, 369, 1966.
29. Schorn, K. and Hochstrasser, K., Biochemical investigations of nasal secretions, Acta Otorhinolaryngol. Bel., 33, 603, 1979.
30. Shehamer, J., Maron, Z., and Kaliner, M., The constituents of nasal secretion, Ear Nose Throat J., 63, 31, 1984.
31. Fabricant, N. D., The pH of the throat, nose, and ear, Eye Ear Nose Throat Mon., 43, 60, 1964.
32. Ewert, G., On the mucus flow rate in the human nose, Acta Otolaryngol. (Stock, suppl.), 200, 1, 1965.
33. Laurenzi, G. A., The mucociliary stream, J. Occup. Med., 15, 174, 1973.
34. Proctor, D. F. and Wagner, H. N., Clearance of particle from the human nose, Arch. Environ. Health, 11, 366, 1965.
35. Sakakura, Y., Ukai, K., Majima, Y., Murai, S., Harada, T., and Miyoshi, Y., Nasal mucociliary clearance under various conditions, Acta Otolaryngol., 96, 167, 1983.
36. Ghana, N. and Hinderer, K. H., Fine structure of the blood vessels of the human nasal respiratory mucosa, Ann. Otol. Rhinol. Laryngol., 78, 865, 1969.
37. Lansley, A. B., Mucociliary clearance and drug delivery via the respiratory tract, Adv. Drug. Del. Rev., 11, 299, 1993.
38. Washington, N., Wilson, C. G., and Washington, C., Pulmonary drug delivery, in Physiological pharmaceutics: Biological barriers to drug absorption. Wilson, C. G. and Washington, N., Ellis., Ellis Horwood, UK, 1989.
39. Gil, J., Comparative morphology and ultrastructure of the airways, in Mechanisms in respiratory toxicology, 2, Witschi, H. and Netlesheim, P., Eds., CRC Press, Boca Raton, FL, 1982.
40. Davies, C. N., A comparison between inhaled dust and the dust recovered from human lungs, Health Physiol., 10, 1029, 1964.
41. Schneeburger, E. E., Structural basis for some permeability properties of the air-blood barrier, Fed. Proc., 37, 2471, 1978.
42. Taylor, A. E. and Garr, K. A., Estimation of equivalent pore radii of pulmonary capillary and alveolar membranes, Am. J. Physiol., 218, 1133, 1970.
43. Simonds, A. K., Newman, S. P., Johnson, M. A., Talaee, N., Lee, C. A., and Clarke, S. W., Alveolar targeting of aerosol pentamidine, Am. Rev. Resp. Dis., 141, 827, 1990.
44. Lethem, M. I., The role of tracheobronchiol mucus in drug administration to the airways, Adv. Drug Del. Rev., 11, 271, 1993.
45. Rytting, J. H., Rectal route of peptide and protein drug delivery, in Peptide and Protein Drug Delivery. Lee, V. H. L., Ed., Marcel Dekker, New York, 579, 1992.
46. De Boer, A. G., De Leede, G. J., and Breimer, D. D., Drug absorption by sublingual and rectal routes, Br. J. Anesth., 56, 69, 1984.
47. De Boer, A. G., van Hoogdalem, E. F., and Breimer, D. D., (D) Routes of Delivery: Case studies. (4) Rate controlled rectal peptide drug absorption enhancement, Adv. Drug Del. Rev., 8, 237, 1992.
48. Goldman, H. and Antonioli, D. A., Mucosal biopsy of the rectum, colon, and distant ileum, Human Pathol., 13, 981, 1982.
49. Lorenzsonn, V. and Trier J. S., The fine structure of human rectal mucosa: The epithelia, lining of the base of the crypt, Gastroenterol., 55, 88, 1968.
50. Hafez, E. S. E., The human vagina, Elsevier/North Holland Biomedical Press, Amsterdam, 1978.
51. Ridley, D. M., The genital mucosa, in The Physiology and Pathophysiology of the Skin, 6. Jarrett, A., Ed., Academic Press, London, England, 1979, 1980.
52. Chien, Y. W., Vaginal Drug Delivery and Delivery Systems, in Novel Drug Delivery Systems, 2nd ed., Chien, Y. W., Ed., Marcel Dekker, New York, 529, 1992.
53. Okada, H., Vaginal route of peptide and protein drug delivery, in Peptide and Protein Drug Delivery, Lee, V. H. L., Ed., Marcel Dekker, New York, 633, 1992.
54. Hafez, E. S. E., Female reproductive organs, in Human Reproductive Physiology, Hafez, E. S. E., Ed., Ann Arbor Science, Ann Arbor, MI., 19, 1978.
55. Wingerd, B. D., Human Anatomy and Rabbit Dissection, Johns Hopkins Univ. Press, Baltimore, MD, 120, 1984.
56. Chien, Y. W., Mucosal drug delivery: Potential routes for noninvasive systemic administration, in Novel Drug Delivery Systems, Chien, Y. W., Ed., Marcel Dekker, New York, 197, 1992.
57. Rojanasakul, Y., Wang, L., Bhat, M., Glover, D. D., Malanga, C. J., and Ma, J. K. H., The transport barrier of epithelia: A comparative study on membrane permeability and charge selectivity in the rabbit, Pharm. Res., 9, 1029, 1992.
58. Verhoef, J. C., Brodde, H. E., de Boer, A. G., Bouwstra, J. A., Junginger, H. E., Merkus, F. W. H. M., and Breimer, D. D., Transport of peptide and protein drugs across biological membranes, Eur. J. Drug Metab. Pharmacokin., 15, 83, 1990.
59. Hayasbi, M., Hirasawa, T., Muraoka, T., Shiga, M., and Awazu, S., Comparison of water influx and sieving coefficients in rat, jejunal, rectal, and nasal absorptions of antipyrine, Chem. Pharm. Bull., 33, 2149, 1985.
60. Corbo, D. C., Liu, J.-C., and Chien, Y. W., Characterization of the barrier properties of mucosal membranes, J. Pharm. Sci., 79, 202, 1990.
61. Nair, M. and Chien, Y. W., Buccal delivery of protestation steroids: I. Characterization of barrier properties and effect of penetrant hydrophilicity, Int. J. Pharm., 89, 41, 1993.
62. Chien, Y. W. and Nair, M., Biomembrane permeation and stereochemistry, J. Pharm. Sci., 82, 342, 1993.
63. Nair, M. and Chien, Y. W., Effect of stereochemistry of substituent groups on permeation across biological membranes, Sci. Tech. Pharm. Pharm. Sci. (STP Pharma.), 3, 425, 1993.
64. Sandow, J., Clinical applications of LHRH and its analogs, Clin. Endocrinol., 18, 571, 1983.
65. Lensay, A., Clinical appreciation of LHRH analog formulations, Horm. Res., 32 (supp 1), 93, 1989.
66. Handelsman, D. J. and Swerdloff, R. S., Pharmacokinetics of gonadotropin-releasing hormone and its analogs, Endocrin. Rev., 7, 95, 1986.
67. Okada, H., Yamazaki, I., Ogawa, Y., Hirai, S., Yashiki, T. And Mima, H., Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (Leuprolide) in rats. I. Absorption by various routes and absorption enhancement, J. Pharm. Sci., 71, 1367, 1982.
68. Yamazaki, I., Serum concentration patterns of an LHRH agonist, gonadotropins, and sex steroids after subcutaneous, vaginal, rectal, and nasal administration of the agonist to pregnant rats, J. Reprod. Fert., 12, 129, 1984.
69. Yamazaki, I., Differences in the pregnancy-terminating effectiveness of an LHRH analog by subcutaneous, vaginal, rectal, and nasal routes in rats, Endocrinol. Jpn., 29, 415, 1982.
70. Larsen, C., Jorgensen, M. N., Tomeerup, B., Mygind, N., Dagrosa, E. E., Grigoleit, H.-G., and Malerczyk, V., Influence of experimental rhinitis on the gonadotropin response to intranasal administration of buserelin, Eur. J. Clin. Pharmacol., 33, 155, 1987.
71. Chan, R. L., Henzl, M. R., LePage, E., LaFargue, J., Nerenberg, C. A., Anik, S., and Chaplin, M. D., Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone, Clin. Pharm. Ther., 44, 275, 1988.
72. Chaplin, M. D., Bioavailability of nafarelin in healthy volunteers, Am. J. Obstet. Gynecol., 166, 762, 1992.
73. Adjei, A., Sundberg, D., Miller, J., and Chun, A., Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res., 9, 244, 1992.
74. Bennett, D. B., Tyson, E., Nuremberg, C. A., Mah, S., de Groot, J. S., and Teitelbaum, Z., Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized rat, Pharm. Res., 11, 1048, 1994.
75. Zhou, X. H. and Li Wan Po, A., Comparison of enzyme activities of tissues lining portals of absorption of drugs: Species differences, Int. J. Pharm., 70, 271, 1991.
76. Banga, A. K. and Chien, Y. W., Systemic delivery of therapeutic peptides and proteins, Int. J. Pharm., 48, 15, 1988.
77. Lee, V. H. L., Enzymatic barriers to peptide and protein absorption, Crit. Rev. Ther. Drug Carrier Sys., 5, 69, 1988.
78. Wearley, L. L., Recent progress in protein and peptide delivery by noninvasive routes, Crit. Rev. Ther. Drug Carrier Sys., 8, 331, 1991.
79. Zhou, X. H., Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs, J. Contr. Rel., 29, 239, 1994.
80. Chien, Y. W., Recent advances in noninvasive systemic delivery of pharmaceuticals and biopharmaceuticals, Drug Dev. Ind. Pharm., 20, 417, 1994.
81. Bond, J. S. and Beynon, R. J., Proteolysis and physiological regulation, Mol. Asp. Med., 9, 173, 1987.
82. Schwartz, J. C., Malfroy, B., and De La Baume, S., Biological inactivation of enkephalins and the role of enkephalin-depeptidyl-carboxypeptidase ("enkephalinase") as neuropeptidase, Life Sci., 29, 1715, 1981.
83. Dodda Kashi, S. and Lee, V. H. L., Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases, Life Sci., 38, 2019, 1986.
84. Sayani, A. P., Chun, I. K., and Chien, Y. W., Transmucosal delivery of leucine enkephalin: Stabilization in rabbit enzyme extracts and enhancement of permeation through mucosae, J. Pharm. Sci., 83, 1179, 1993.
85. Hussain, M. A., Seetharam, R., Wilk, R. R., Aungst, B. J., and Kettner, C. A., Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amino acids, J. Pharm. Sci., 84, 62, 1995.
86. Stratford, R. E. and Lee, V. H. L., Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery, Int. J. Pharm., 30, 73, 1986.
87. Lee, V. H. L., Traver, R. D., and Taub, M. E., Enzymatic barriers to protein and peptide delivery, in Peptide and Protein Drug Delivery., Lee, V. H. L., Ed., Marcel Dekker, New York, 303, 1992.
88. Redding, T. W., Kastin, A. J., Gonzalez-Barcena, D., Coy, D. H., Schalch, D. S., and Schally, A. V., The half-life, metabolism, and excretion of tritiated luteinizing hormone-releasing hormone (LHRH) in man, J. Clin. Endocrinol. Metab., 37, 626, 1973.
89. Griffiths, E. C. and McDermott, J. R., Enzymic inactivation of hypothalamic regulatory hormones, Mol. Cell. Endocrinol., 33, 1, 1983.
90. Horsthemke, B., Knisatschek, H., Rivier, J., Sandow, J., and Bauer, K., Degradation of luteinizing hormone-releasing hormone and analogs by adenohypophyseal peptidases, Biochem. Biophys. Res. Comm., 100, 753, 1981.
91. Bennett, H. P. J. and McMartin, C., Peptide hormones and their analogs: Distribution, clearance from the circulation, and inactivation in vivo, Pharmacol. Rev., 30, 247, 1979.
92. Sandow, J., Chemistry and metabolism of LHRH and its analogs, in LHRH and its analogues: Their use in gynecological practice. Shaw, R. W. and Marshall, J. C., Eds., Wright, Boston, 88, 1989.
93. De La Cruz, A., De La Cruz, K., Arimura, A., Coy, D. H., Vilchez-Martinez, J. A., Coy, E. J., and Schally, A. V., Gonadotropin-releasing activity of two highly active and long-acting analogs of luteinizing hormone-releasing hormone after subcutaneous, intravaginal, and oral administration, Fert. Steril, 26, 894, 1975.
94. 2]-LHRH ethylamide on serum LH levels in ovariectomized, steroid-blocked rats, Proc. Soc. Exp. Biol. Med., 148, 1009, 1975.
95. Yamamoto, A., Hayakawa, E., and Lee, V. H. L., Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit, Life Sci., 47, 2465, 1990.
96. Schilling, R. J. and Mitra, A. K., Degradation of insulin by trypsin and alpha-chymotrypsin, Pharm. Res., 8, 721, 1991.
97. Gizurarson, S. and Bechgaard, E., Evaluation of nasal enzyme activity towards insulin. In vitro, Chem. Pharm. Bull., 39, 2155, 1991.
98. Lee, M. L., Transmucosal delivery and absorption of calcitonin: kinetics and enhancement of permeation. Ph.D. Thesis, Rutgers University, NJ, 1993.
99. Lee, Y. L., Oral mucosa controlled drug delivery for LHRH and development of mucoadhesive systems, Ph.D. Thesis, Rutgers University, NJ, 1994.
100. Moss, J. and Bundgaard, H., Kinetics and pattern of degradation of thyrotropin releasing hormone (TRH) in human plasma, Pharm. Res., 7, 751, 1990.
101. Sayani, A. P., Kim, D. D., Frenkl, T. L., Chun, I. K., Wang, Y. J., and Chien, Y. W., Transmucosal delivery of enkephalins: Comparative enhancing effects of dihydrofusidates and bile salts, Sci. Tech. Pharm. Pharm. Sci. (STP Pharma.), 4, 470, 1994.
102. Hirai, S., Yashiki, T., and Mima, H., Mechanisms for the enhancement of the nasal absorption of insulin by surfactants, Int. J. Pharm., 9, 173, 1981.
103. Nakajinia, S., Kaya, K., and Hazako, T., Protection of endogenous enkephalin degradation from peptidases in human serum by actinonin, Neuropeptides, 13, 201, 1989.
104. Hussain, M. A., Shenvi, A. B., Rowe, S. M., and Shefter, E., The use of α-aminoboronic acid derivatives to stabilize peptide drugs during their intranasal absorption, Pharm. Res., 6, 186, 1989.
105. Hussain, M. A., Koval, C. A., Shenvi, A. B., and Aungst, B. J., Recovery of rat nasal mucosa from the effects of aminopeptidase inhibitor, J. Pharm. Sci., 79, 398, 1990.
106. Faraj, J. A., Hussain, A. A., Aramaki, Y., Iseki, K., Kagoshima, M., and Dittert, L. W., Mechanism of nasal absorption of drugs. III. Nasal absorption of leucine enkephalin, J. Pharm. Sci., 79, 698, 1990.
107. 3H]-leucine enkephalin, J. Pharm. Sci., 79, 768, 1990.
108. Chun, I. K. and Chien, Y. W., Stabilization of methionine enkephalin in various rabbit mucosal extracts by enzyme inhibitors, Int. J. Pharm., 121, 217, 1995.
109. Altstein, M., Bachar, E., Vogel, Z., and Blumberg, S., Protection of enkephalins from enzymatic degradation utilizing selective metal chelating inhibitors, Eur. J. Pharmacol., 91, 353, 1983.
110. Yamamoto, A., Hayakawa, E., Kato, Y., Nishiura, A., and Lee, V. H. L., A mechanistic study on enhancement of rectal permeability to insulin in the albino rabbit, J. Pharmacol. Exp. Ther., 263, 25, 1992.
111. Hussain, M. A., Lim, M. S. L., Krishnaswamy, K. S., Rogers, N. J., Hidalgo, R., and Kettner, C. A., A phosphinic acid dipeptide analog to stabilize peptide drugs during their intranasal absorption, Pharm Res, 9, 626, 1992.
112. Nakada, Y., Miyake, M., and Awata, N., Some factors affecting the vaginal absorption of human calcitonin in rats, Int. J. Pharm., 89, 169, 1993.
113. Lee, V. H. L., Yamamoto, A., and Kompella, U. B., Mucosal penetration enhancers for facilitation of peptide and protein drug absorption, Crit. Rev. Ther. Drug Carrier Sys., 8, 91, 1991.
114. De Ponti, R. and Lardini, E., Use of chemical enhancers for nasal drug delivery, Drug Dev. Ind. Pharm., 17, 1419, 1991.
115. O'Hagan, D. T. and Illum, L., Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine, Crit. Rev. Ther. Drug Carrier Sys., 7, 35, 1990.
116. Hochman, J. and Arturrson, P., Mechanisms of absorption enhancement and tight junction regulation, J. Contr. Rel., 29, 253, 1994.
117. Gordon, G. S., Moses, A. C., Silver, R. D., Flier, J. S., and Carey, M. C., Nasal absorption of insulin: Enhancement by hydrophobic bile salts, Proc. Nat'l. Acad. Sci. USA, 82, 7419, 1985.
118. Duchateau, G. S. M. J. E., Zuidema, J., and Merkus, F. W. H. M., Bile salts and intranasal drug absorption, Int. J. Pharm., 31, 193, 1986.
119. Moses, A. C., Flier, J. S., Gordon, G. S., Silver, R. D., and Carey, M. C., Transnasal insulin delivery: structure-function studies of absorption enhancing adjuvants, Clin, Res., 32, 254A, 1984.
120. Hirai, S., Yashiki, M., and Mima, H., Effects of surfactants on the nasal absorption of insulin in rats, Int. J. Pharm., 9, 165, 1981.
121. Hanson, M., Gazdick, G., Cahill, J., and Augustine, M., Intranasal delivery of the peptide salmon calcitonin, in Delivery systems for peptide drugs. Davis, S. S., Illum, L. and Tomlinson, E., Eds., Plenum Press, New York, 233, 1986.
122. Chun, I. K., Kim, D. D., Wang, Y. J., and Chien, Y. W., Transmucosal delivery of methionine enkephalin. III. Permeation enhancement by combinations of enzyme inhibitors and enhancers, Int. J. Pharm., submitted for publication, 1993.
123. Gumbiner, B. and Simons, K., Functional assay for proteins involved in establishing an epithelial occluding barrier, J. Cell Biol., 102, 457, 1986.
124. Suzuka, T., Furuya, A., Kamada, A., and Nishihata, T., Effect of phenothiazines, disodium ethylenediaminetetraacetic acid and diethyl maleate on in vitro rat colonic transport of cefmetazole and inulin, J. Pharmacobiodyn., 10, 63, 1987.
125. Su, K. S. E., Campanale, K. M., Mendelsohn, L. G., Kerchner, G. A., and Gries, C. L., Nasal delivery of polypeptides. I. Nasal absorption of enkephalins in rats, J. Pharm. Sci., 74, 394, 1985.
126. Hersey, S. J. and Jackson, R. Y., Effect of bile salts on nasal permeability in vitro, J. Pharm. Sci., 76, 876, 1987.
127. Maitani, Y., Uchida, N., Nakagaki, M., and Nagai, T., Effect of bile salts on the nasal mucosa: membrane potential measurement, Int. J. Pharm., 69, 21, 1991.
128. Schipper, N. G. M., Verhoef, J. C., and Merkus, F. W. H. M., The nasal mucociliary clearance: Relevance to nasal drug delivery, Pharm. Res., 8, 807, 1991.
129. Jain, L. and Li Wan Po, A., Effects of insulin and nasal absorption enhancers on ciliary activity, Int. J. Pharm., 95, 101, 1993.
130. Merkus, F. W. H. M., Schipper, N. G. M., Hermens, W. A. J. J., Romeijn, S. G., and Verhoef, J. C., Absorption enhancers in nasal drug delivery: efficacy and safety, J. Contr. Rel., 24, 201, 1993.
131. Longnecker, J. P., Moses, A. C., Flier, J. S., Silver, R. D., Carey, M. C., and Dubovi, E. J., Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep, J. Pharm. Sci., 76, 351, 1987.
132. Baldwin, P. A., Klingbeil, C. K., Grimm, C. J., and Longenecker, J. P., The effect of sodium tauro-24,25-dihydrofusidate on the nasal absorption of human growth hormone in three animal models, Pharm. Res., 7, 547, 1990.
133. Lee, W. A., Narog, B. A., Patapoff, T. W., and Wang, Y. J., Intranasal bioavailability of insulin powder formulations: effect of permeation enhancer-to-protein ratio, J. Pharm. Sci., 80, 725, 1991.
134. Deurloo, M. J. M., Hermens, W. A. J. J., Romeijn, S. G., Verhoef, J. C., and Merkus, F. W. H. M., Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats, Pharm. Res., 6, 853, 1989.
135. Lee, W. A., Lu, H. F.-L., Maffuid, P. W., Botet, M. T., Baldwin, P. A., Benkert, T. A., and Klingbeil, C. K., The synthesis, characterization, and biological testing of a novel class of mucosal permeation enhancers, J. Contr. Rel., 22, 223, 1992.
136. van Hoogdalem, E. J., Vermeij-Kerrs, C., De Boer, A. G., and Breimer, D. D., Topical effects of absorption-enhancing agents on the rectal mucosa of rats in vivo, J. Pharm. Sci., 79, 886, 1990.
137. Ennis, R. D., Borden, L., and Lee, W. A., The effects of permeation enhancers on the surface morphology of the rat nasal mucosa: A scanning electron microscopy, Pharm. Res., 7, 468, 1990.
138. Hermens, W. A. J. J., Hooymans, P. M., Verhoef, J. C., and Merkus, F. W. H. M., Effects of absorption enhancers on human nasal tissue movement in vitro, Pharm. Res., 7, 144, 1990.
139. Chandler, S. G., Illum, L., and Thomas, N. W., Nasal absorption in rats. II Effects of enhancers on insulin absorption and nasal histology, Int. J. Pharm., 76, 61, 1991.
140. Kissel, T., Drewe, J., Bantle, S., Rummelt, A., and Beglinger, C., Tolerability and absorption of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects, Pharm. Res., 9, 52, 1992.
141. Lee, W. A., Ennis, R. D., Longenecker, J. P., and Bengtsson, P., The bioavailability of intranasal calcitonin in healthy volunteers with and without a permeation enhancer, Pharm. Res., 11, 747, 1994.
142. Raehs, S. C., Sandow, J., Wirth, K., and Merkle, H. P., The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats, Pharm. Res., 5, 689, 1988.
143. van Hoogdalem, E. J., Heijligers-Feijen, C. D., Mathot, R. A. A., Wackwitz, A. T. E., van Bree, J. B. M. M., Verhoef, J. C., de Boer, A. G., and Breimer, D. D., Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by sodium tauro-24,25-dihydrofusidate in conscious rats, J. Pharm. Exp. Ther., 251, 741, 1989.
144. van Hoogdalem, E. J., Heijligers-Feijen, C. D., Verhoef, J. C., de Boer, A. G., and Breimer, D. D., Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats, Pharm. Res., 7, 180, 1990.
145. Schipper, N. G. M., Hermens, W. A. J. J., Romeijn, S. G., Verhoef, J. C., and Merkus, F. W. H. M., Nasal absorption of 17-β-estradiol and progesterone from a dimethyl-β-cyclodextrin inclusion formulation in rats, Int. J. Pharm., 64, 61, 1990.
146. Schipper, N. G. M., Verhoef, J. C., Romeijn, S. G., and Merkus, F. W. H. M., Absorption enhancers in nasal insulin delivery and their influence on nasal ciliary functioning, J. Contr. Rel., 21, 173, 1992.
147. Szejtli, J. C., Cyclodextrins in drug formulations, Pharm. Tech. Int., 3, 15, 1991.
148. Verhoef, J. C., Schipper, N. G. M., Romeijn, S. G., and Merkus, F. W. H. M., The potential of cyclodextrins as absorption enhancers in nasal delivery of peptide drugs, J. Contr. Rel., 29, 351, 1994.
149. Uekama, K., Fujinaga, F., Hirayama, F., Otagini, M., and Yamasaki, M., Inclusion complexations of steroid hormones with cyclodextrins in water and solid phases, Int. J. Pharm., 10, 1, 1982.
150. Stratton, C. F., Cyclodextrins and biological macromolecules, BioPharm., 4, 44, 1991.
151. Merkus, F. W. H. M., Verhoef, J. C., Romeijn, S, G., and Schipper, N. G. M., Absorption-enhancing effect of cyclodextrins on intranasally administered insulin in rats, Pharm. Res., 8, 588, 1991.
152. Shimamoto, T., Nasal and depot formulations of leuprolide, J. Androl., 8, S14, 1989.
153. Adjei, A., Sundberg, D., Miller, J., and Chun, A., Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res., 9, 244, 1992.
154. Watanabe, Y., Matsumoto, Y., Kawamoto, K., Yazawa, S., and Matsumoto, M., Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits, Chem. Pharm. Bull, 40, 3100, 1992.
155. Watanabe, Y., Matsumoto, Y., Seki, M., Takase, M., and Matsumoto, M., Absorption enhancement of polypeptide drugs by cyclodextrins: I. Enhanced rectal absorption of insulin from hollow type suppositories containing insulin and cyclodextrins in rabbits, Chem. Pharm. Bull., 40, 3042, 1992.
156. Irie, T., Wakamatsu, K., Arima, H., and Uekama, K., Enhancing effects of cyclodextrins on nasal absorption of insulin in rats, Int. J. Pharm., 84, 129, 1992.
157. Irwin, W. J., Dwivedi, A. K., Holbrook, P. A., and Dey, M. J., The effect of cyclodextrins on the stability of peptides in nasal enzymatic systems, Pharm. Res., 11, 1698, 1994.
158. Shao, Z., Krishnamoorthy, R., and Mitra, A. K., Cyclodextrins as nasal absorption promoters of insulin: Mechanistic evaluations, Pharm. Res., 9, 1157, 1992.
159. Schipper, N. G. M., Romeijn, S. G., Verhoef, J. C., and Hermens, F. W. H. M., Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits powder more effective than liquid formulations, Pharm. Res., 10, 682, 1993.
160. Lee, W. A. and Longenecker, J. P., Intranasal delivery of proteins and peptides, BioPharm., April, 30-37, 1988.
161. Chien, Y. W., Intranasal delivery of peptides and proteins, in Nasal Systemic Drug Delivery, Chien, Y. W., Ed., Marcel Dekker, New York, 89, 1989.
162. Illum, L., The nasal delivery of peptides and proteins, Trends in Biotech., 9, 284, 1991.
163. Hsieh, D. S., Understanding permeation enhancement technologies, in Drug Permeation Enhancement: Theory and Applications. Hsieh, D. S., Ed., Marcel Dekker, New York, 3, 1994.
164. Vickery, B. H., Anik, S., Chaplin, M., and Henzl, M., Intranasal administration of nafarelin acetate: concentration and therapeutic applications, in Transnasal Systemic Medications, Chien, Y W., Ed., Elsevier, Amsterdam, 201, 1985.
165. Sandow, J. and Petni, W., Intranasal administration of peptides - biological activities and therapeutic efficiencies, in Transnasal Systemic Medications, Chien, Y. W., Ed., Elsevier, Amsterdam, 183, 1985.
166. Grossman, A., Fabbri, A., Goldberg, P. L., and Nesser, G. M., Two new methods of desmopressin (DDAVP) administration, Br. J. Med., 280, 1215, 1989.
167. Sjoberg, H. and Luft, R., Nasal spray of synthetic vasopressin for the treatment of diabetes insipidus, Lancet, 1, 1159, 1963.
168. Muller, K. and Osler, M., A comparison of intravenous, intranasal, and transbuccal oxytocin (Partocon), Acta. Obstet. Gynecol. Scand., 46, 346, 1967.
169. Newton, M. and Elgi, G. E., The effect of intranasal administration of oxytocin on the let-down of milk in lactating women, Acta. Obstet. Gynecol. Scand., 76, 103, 1958.
170. Sarkar, M. A., Drug metabolism in the nasal mucosa, Pharm. Res., 9, 1, 1992.
171. Su, K. S. E., Campanale, K. M., Mendelsohn, L. G., Kerchner, G. A., and Gries, C. L., Nasal delivery of polypeptides. I. Nasal absorption of enkephalins in rats, J. Pharm. Sci., 74, 394, 1985.
172. McMartin, C., Hutchinson, L. E. F., Hyde, R., and Peters, G. E., Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity, J. Pharm. Sci., 76, 535, 1987.
173. Donovon, M. D., Flynn, G. L., and Amidon, G. L., The molecular weight dependence of nasal absorption: The effect of absorption enhancers, Pharm. Res., 7, 808, 1990.
174. Yamamoto, A., Morita, T., Hashida, M., and Sezaki, H., Effect of absorption promoters on the nasal absorption of drugs with various molecular weights, Int. J. Pharm., 93, 91, 1993.
175. Kubo, H., Hosoya, K., Natsume, H., Sugibayashi, K., and Morimoto, Y., In vitro permeation of several model drugs across rabbit nasal mucosa, Int. J. Pharm., 103, 27, 1994.
176. Wheatley, M. A., Dent, J., Wheeldon, E. B., and Smith, P. L., Nasal drug delivery: An in vitro characterization of transepithelial electrical properties and fluxes in the presence or absence of enhancers, J. Contr. Rel., 8, 167, 1988.
177. Ohkawi, T., Ando, H., Watanabe, S., and Miyake, Y., Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats, J. Pharm. Sci., 74, 550, 1985.
178. Ohkawi, T., Ando, H., Kakimoto, F., Uesugi, K., Watanabe, S., Miyake, Y., and Kayano, M., Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. II. Histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity, J. Pharm. Sci., 76, 695, 1987.
179. Ohkawi, T., Ishii, M., Aoki, S., Tatsuishi, K., and Kayano, M., Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. III. In vitro membrane permeation test and determination of apparent partition coefficient of secretin, Chem. Pharm. Bull., 37, 3359, 1989.
180. Hussein, A., Hamadi, S., Kagoshima, M., Iseki, K., and Dittert, L., Does increasing the lipophilicity of peptides enhance their nasal absorption, J. Pharm. Sci., 80, 1180, 1991.
181. Donnelly, A., Evans, J. P., Kellaway, I. W., Farr, S. J., Taylor, G., Tudball, N., and Gibson, M., Development of model compounds designed to investigate factors influencing nasal absorption of peptides and proteins, Proc. Int. Symp. Contr. Rel. Bioactive Mater., 21, 889, 1994.
182. Harris, A. S., Ohlin, M., Svensson, E., Lethagen, S., and Nilsson, I. M., Effect of viscosity on the pharmacokinetics and biological response to intranasal absorption desmopressin, J. Pharm. Sci., 78, 470, 1989.
183. Gonda, I. and Gipps, E., Model of disposition of drugs administered into the human nasal cavity, Pharm. Res., 7, 69, 1990.
184. Chandler, S. G., Illum, L., and Thomas, N. W., Nasal absorption in the rat. I. A method to demonstrate the histological effects of nasal formulations, Int. J. Pharm., 70, 19, 1991.
185. Henzl, M. R., Gonadotropin releasing hormone analogs: Update on new findings, Am. J. Obstet. Gynecol., 166, 757, 1992.
186. Adjei, A., Sundberg, D., Miller, J., and Chun, A., Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans, Pharm. Res., 9, 244, 1992.
187. Igawa, T., Maitani, Y., Machida, Y., and Nagai, T., Effect of absorption promoters in intranasal administration of human fibroblast interferon as a powder dosage form in rabbits, Chem. Pharm. Bull., 37, 418, 1989.
188. Baglioni, C. and Phipps, R. J., Nasal absorption of interferon: Enhancement by surfactant agents, J. Interferon Res., 10, 497, 1990.
189. Tengamnuay, P., Shao, Z., and Mitra, A. K., Systemic absorption of L- and D-Phenylalanine across the rat nasal mucosa. Life Sci., 48, 1477, 1991.
190. Morimoto, K., Yamaguchi, H., Iwakura, Y., Morisaka, K., Ohashi, Y., and Nakai, Y., Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analog, Pharm. Res., 8, 471, 1991.
191. Morimoto, K., Yamaguchi, H., Iwakura, Y., Miyazaki, M., Nakatani, E., Iwamoto, T., Ohashi, Y., and Nakai, Y., Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analog, Pharm. Res., 8, 1175, 1991.
192. Fisher, A. N., Farraj, N. F., O'Hagan, D. T., Jabbal-Gill, I., Johansen, B. R., Davis, S. S., and Illum, L., Effect of L-α-lysophosphatidylcholine on the nasal absorption of human growth hormone in three animal species, Int. J. Pharm., 74, 147, 1991.
193. Kararli, T. T., Needham, T. E., Schoenhard, G., Baron, D. A., Schmidt, R. E., Katz, B., and Belonio, B., Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations, Pharm. Res., 9, 1024, 1992.
194. Murakami, T., Kishimoto, M., Kawakita, H., Kisaki, M., Kojima, Y., Higashi, Y., Amagase, H., Fuwa, T., and Yata, N., Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoters and synthetic polymer in rats, Eur. J. Drug Metab. Pharmacokin., Spec. No. 3, 125, 1991.
195. Machida, M., Sano, K., Arakawa, M., Hayashi, M., and Awazu, S., Absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) from rat nasal mucosa, Pharm. Res., 10, 1372, 1993.
196. Watanabe, Y., Matsumoto, Y., Yamaguchi, M., Kikuchi, R., Takayama, K.,
197. Schipper, N. G. M., Verhoef, J. C., De Lannoy, L. M., Romeijn, S. G., Brakkee, J. H., Weigant, V. M., Gispen, W. H., and Merkus, F. W. H. M., Nasal administration of an ACTH (4-9) peptide analog with DMβCD as an absorption enhancer, Br. J. Pharmacol., 110, 1335, 1993.
198. Jorgensen, L. and Bechgaard, E., Intranasal absorption of angiopeptin: In vitro study of absorption and enzymatic degradation, Int. J. Pharm., 99, 165, 1993.
199. Hazama, M., Mayumi, A. A., Miyazaki, T., Hinuma, S., and Fujisawa, Y., Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of E coli heat-labile enterotoxin and interleukin-2, Immunology, 78, 643, 1993.
200. Rathborne, M. J., Human buccal absorption. I. A method for estimating the transfer kinetics of drugs across the human buccal membrane, Int. J. Pharm., 69, 103, 1991.
201. Rathborne, M. J., Human buccal absorption. II. A comparative study of the human buccal absorption of some para hydroxybenzoic acid derivatives using the buccal absorption test and a buccal perfusion cell, Int. J. Pharm., 74, 189, 1991.
202. Rathborne, M. J., Drummond, B. K., and Tucker, I. G., The oral cavity as a site for systemic drug delivery, Adv. Drug Del. Rev., 13, 1, 1994.
203. Merkle, H. P., Anders, R., Sandow, J., and Schurr, W., Self-adhesive patches for buccal delivery of peptides, Proc. Int. Symp. Contr. Rel. Bioactive Mater., 12, 85, 1988.
204. Ishida, M., Machida, Y., Nambu, N., and Nagai, T., New mucosal dosage forms of insulin, Chem. Pharm. Bull., 29, 810, 1981.
205. Nagai, T., Topical mucosal adhesive dosage forms, Med. Res. Rev., 6, 227, 1986.
206. Nagai, T. and Machida, Y., Mucosal adhesive dosage forms, Pharm. Int., 6, 196, 1985.
207. Lehr, C. M., Bouwstra, J. A., Kok, W., De Boer, A. G., Tukker, J. J., Verhoef, J. C., Breimer, D. D., and Junginger, H. E., Effects of the mucoadhesive polymer carbophil on the intestinal absorption of a peptide drug in the rat, J. Pharm. Pharmacol., 4, 402, 1992.
208. Luessen, H. L., Lehr, C. M., Rentel, C. O., Noach, A. B. J., de Boer, A. G., Verhoef, J. C., and Junginger, H. E., Bioadhesive polymers for the peroral delivery of peptide drugs, J. Contr. Rel., 29, 329, 1994.
209. Oh, C. K. and Ritschel, W. A., Biopharmaceutical aspects of buccal absorption of insulin, Meth. Find. Exp. Clin. Pharmacol., 12, 205, 1990.
210. Oh, C. K. and Ritschel, W. A., Absorption characteristics of insulin through the buccal mucosa, Meth. Find. Exp. Clin. Pharmacol., 12, 275, 1990.
211. Heiber, S. J., Ebert, C. D., Dave, S. C., Smith, K., Kim, S. W., and Mix, D., In-vivo buccal delivery of calcitonin, Proc. Int. Symp. Contr. Rel. Bioactive Mater., 21, 269, 1994.
212. Lee, Y. L. and Chien, Y. W., Oral mucosal delivery of LHRH. I. Physicochemical and enzymatic stability of LHRH, Pharm. Res., 11, S300, 1994.
213. Lee, Y. L. and Chien, Y. W., Oral mucosal delivery of LHRH. II. Enhancement of permeation by bile salts and evaluation of mechanisms, Pharm. Res., 11, S300, 1994
214. Lee, Y. L. and Chien, Y. W., Oral mucosal delivery of LHRH. III. Long-acting delivery by bilayer mucoadhesive polymer systems, Pharm. Res., 11, S300, 1994
215. Schneeburger, E. E., Ultrastructural basis for alveolar-capillary permeability to protein, Ciba Found. Symp., 38, 3, 1976.
216. De Fouw, D. O., Ultrastructural features of alveolar epithelial transport, Am. Rev. Resp. Dis., 127, S9, 1983.
217. Patton, J. S. and Platz, R. M., Routes of delivery: Case studies (2) Pulmonary delivery of peptides and proteins for systemic action, Adv. Drug Del. Rev., 8, 179, 1992.
218. Schanker, L. S. and Hemberger, J. A., Relation between molecular weight and pulmonary absorption rate of lipid-insoluble compounds in neonatal and adult rats, Biochem. Pharmacol., 32, 2599, 1983.
219. Effros, R. M. and Mason, G. R., Measurements of pulmonary epithelial permeability in vivo, Am. Rev. Resp. Dis., 127, S59, 1983.
220. Elliot, R. B., Edgar, B. W., Pilcher, C. C., Quested, C., and McMaster, J., Parenteral absorption of insulin from the lung in diabetic children, Aust. Fed. J., 23, 293, 1987.
221. Colthorpe, P., Farr, S. J., Taylor, G., Smith, I. J., and Wyatt, D., The pharmacokinetics of pulmonary delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit, Pharm. Res., 9, 764, 1992.
222. Liu, F.-Y., Shao, Z., Kildsig, D. O., and Mitra, A. K., Pulmonary delivery of free and liposomal insulin, Pharm. Res., 10, 228, 1993.
223. Adjei, A., Doyle, R., Pratt, M., Finley, R., and Johnson, E., Bioavailability of leuprolide following intratracheal administration to beagle dogs, Int. J. Pharm., 61, 135, 1990.
224. Adjei, A. and Garren, J., Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers, Pharm. Res., 7, 565, 1992.
225. Adjei, A., Hui, J., Finley, R., Lin, T., Lancaster, J., and Fort, F., Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: Some pharmacokinetic and preclinical issues, Int. J. Pharm., 107, 57, 1994.
226. 1,7)-eel calcitonin by various protease inhibitors in rats, Pharm. Res., 11, 909, 1994.
227. Kobayashi, S., Kondo, S., and Juni, K., Study on the pulmonary delivery of salmon calcitonin in rats: Effects of protease inhibitors and absorption enhancers, Pharm. Res., 11, 1239, 1994.
228. Niven, R. W., Lott, F. D., and Cribbs, J. M., Pulmonary absorption of recombinant human methionyl granulocyte colony-stimulating factor (r-huG-CSF) after intratracheal instillation to the hamster, Pharm. Res., 10, 1604, 1993.
229. Niven, R. W., Lott, F. D., Ip, A. Y., and Cribbs, J. M., Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor, Pharm. Res., 11, 1101, 1994.
230. Task group on lung dynamics, Deposition and retention model for internal dosimetry of the human respiratory tract, Health Phys., 12, 173, 1966.
231. Hickey, A., Pharmaceutical Inhalation Aerosol Technology. Hickey, A., Ed., Marcel Dekker, Inc., New York, 155, 1992.
232. Lindberg, T., Intestinal dipeptidases: Dipeptidase activity in the mucosa of the gastrointestinal tract of the adult human, Acta Physiol. Scand., 66, 437, 1966.
233. Scheline, R. R., Metabolism of foreign compounds by gastrointestinal microorganisms, Pharmacol. Rev., 25, 451, 1973.
234. 2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery, Pharm. Res., 5, 305, 1988.
235. Yoshioka, S., Caldwell, C., and Higuchi, T., Enhanced rectal bioavailability of polypeptides using sodium 5-methoxysalicylate as an absorption promoter J. Pharm. Sci., 71, 593, 1982.
236. Watanabe, Y., Matsumoto, Y., Hori, N., Fanato, H., and Matsumoto, M., Enhanced rectal absorption of insulin in rabbit from hollow-type suppositories containing insulin and glyceryl-1-monooctanoate, Chem. Pharm. Bull., 39, 3007, 1991.
237. van Hoogdalem, E. J., Heijligers-Feijen, C. D., de Boer, A. G., Verhoef J. C., and Brienier, D. D., Rectal absorption enhancement of des-enkephalin-γ-endorphin (DEγE) by medium chain glycerides and EDTA in conscious rats, Pharm. Res., 6, 91, 1989.
238. Aungst, B. J., Rogers, N. J., and Shefter, E., Comparison of nasal, rectal, buccal, sublingual, and intramuscular insulin efficacy and the effects of a bile salt absorption promoter, J. Pharm. Exp. Ther., 244, 23, 1988.
239. Hauss, D. J., Ando, H. Y., Grasela, D. M., and Sugita, E. T., The relationship of salicylate lipophilicity to rectal insulin absorption enhancement and relative lymphatic uptake, J. Pharmacobiodyn., 14, 139, 1991.
240. Mitsuma, T. and Nogimori, M., Changes in plasma thyrotrophin-releasing hormone, thyrotrophin, prolactin, and thyroid hormone levels after intravenous, intranasal or rectal administration of synthetic thyrotrophin-releasing hormone in man, Acta Endocrinol., 107, 207, 1984.
241. Murahashi, N., Kato, A., Koyama, N., Watanabe, S., Yuzuriha, T., and Miyaki, Y., Rectal absorption of E-2078 (dynorphin analog peptide) in rats, J. Pharm. Pharmacol., 41, 770, 1989.
242. Pagani, G., Pagani, M. D., Ganiola, D., Pedroncelli, A., Cortesi, L., Gherardi, F., Gualteroni, L., Tengattini, F., and Montini, M., Hypocalcemic effects of rectal and intramuscular administration of synthetic salmon calcitonin, Int. J. Clin. Pharmacol. Ther. Tox., 29, 329, 1991.
243. Fiore, C. E., Fionto, S., Foti, R., Motta, M., Incognito, C., and Grasso, G., Evaluation of the biological activity of unmodified synthetic eel calcitonin rectal capsules: Comparison with intramuscular administration and placebo, Int. J. Clin. Pharm. Res., 12, 185, 1992.
244. Chien, Y. W., Systemic delivery of peptide-based pharmaceuticals, in Novel Drug Delivery Systems. Chien, Y. W., Ed., Marcel Dekker, New York, 631, 1992.
245. Fisher, N. F., The absorption of insulin from the intestine, vagina, and scrotal sac, Am. J. Physiol., 67, 65, 1923.
246. Touitou, E., Doubrow, M., and Azaz, E., New hydrophilic vehicle enabling rectal and vaginal absorption of insulin, heparin, phenol red, and gentamicin, J. Pharm. Pharmacol., 30, 662, 1978.
247. Morimoto, K., Takeeda, T., Nakamoto, Y., and Morisaka, K., Effective vaginal absorption of insulin in diabetic rats and rabbits using polyacrylic acid aqueous gel bases, Int. J. Pharm., 12, 107, 1982.
248. Richardson, J. L., Minhas, P. S., Thomas, N. W., and Illum, L., Vaginal absorption of propranolol to rats: Absorption and histological effects on the vaginal epithelium, Int. J. Pharm., 56, R1, 1989.
249. Richardson, J. L., Minhas, P. S., Thomas, N. W., and Illum, L., Vaginal absorption of gentamicin to rats: Pharmaceutical and morphological studies using absorption enhancers, Int. J. Pharm., 56, 29, 1989.
250. Richardson, J. L., Thomas, N. W., and Illum, L., Recovery of the rat vaginal epithelium from the histological effects of absorption enhancers, Int. J. Pharm., 77, 75, 1991.
251. Richardson, J. L., Illum, L., and Thomas, N. W., Vaginal absorption of insulin in the rat: Effect of penetration enhancers on insulin uptake and mucosal histology, Pharm. Res., 9, 878, 1991.
252. Richardson, J. L., Farraj, N. F., and Illum, L., Enhanced vaginal absorption of insulin in sheep using lysophosphatidylcholine and a bioadhesive microsphere delivery system, Int. J. Pharm., 88, 319, 1992.
253. Golomb, G., Avramoff, A., and Hoffman, A., A new route of drug administration: Intrauterine delivery of insulin and calcitonin, Pharm. Res., 10, 828, 1993.
254. Robinson, J. R. and Bologna, W. J., Vaginal and reproductive system treatments using a bioadhesive polymer, J. Contr. Rel., 28, 87, 1994.
255. Chen, S. A., Reed, B., Nguyen, T., Gaylord, N., Fuller, G. B., and Mordenti, J., The pharmacokinetics and absorption of recombinant human relaxin in nonpregnant rabbits and rhesus monkeys after intravenous and intravaginal administration, Pharm. Res., 10, 223, 1993.
256. Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., and Morris, H. Z., Identification of two related pentapeptides from the brain with potent opiate agonist activity, Nature, 258, 577, 1975.
257. Miller, R. J. and Cuatrecasas, P., The enkephalins. Peptides with morphine like activity, Naturewissenschaften, 65, 507, 1978.
258. Simon, W. M., Schaz, K., Ganten, U., Stock, H., Schlor, K. H., and Ganten, D., Effects of enkephalins on arterial blood pressure are reduced by propranolol, Clin. Sci. Mol. Med., 55, 2375, 1978.
259. Schaz, K., Stock, G., Simon, W., Schlor, K. H., Unger, T., Rockhold, R. and Ganten, D., Enkephalin effects on blood pressure, heart rate, and baroreceptor reflex, Hypertension, 2, 395, 1980.
260. Olson, G. A., Olson, R. D., and Kastin, A. J., Endogenous peptides: Peptides, 7, 907, 1986.
261. 2-methionine and leucine enkephalinamide and methionine and leucine enkephalinamide), Peptides, 6, 1253, 1985.
262. 5 Enkephalinamide, Pol. J. Pharmacol. Pharm., 38, 641, 1987.
263. Chun, I. K. and Chien, Y. W., Transmucosal delivery of methionine enkephalin. I. Solution stability and kinetics of degradation in various rabbit mucosa extracts, J. Pharm. Sci., 82, 373, 1993.
264. Azria, M., The Calcitonins: Physiology and Pharmacology, Karger, New York, 254, 1989.
265. Austin, L. A. and Heath, H., Calcitonin: physiology and pathophysiology, N. Eng. J. Med., 304, 269, 1981.
266. Heynen, G. and Franchimont, P., The circulating forms of human calcitonin, Pathol. Biol. (Paris), 23, 815, 1975.
267. Hillyard, C. J., Cooke, T. J., Coombes, R. C., Evans, L M., and MacIntyre, I., Normal plasma calcitonin: circadian variation and response to stimuli, Clin. Endocrin. (Oxf.), 6, 291, 1977.
268. Deflos, L. J., Weisman, M. H., Williams, G. W., Karpf, D. B., Frumar, A. M., Davidson, B. J., Parthemore, J. G., and Judd, H. L., Influence of age and sex on plasma calcitonin in human beings, N. Eng. J. Med., 302, 1351, 1980.
269. MacIntyre, I. and Stevenson, J. C., The calcium regulating hormones: recent advances, Biochem. Soc. Trans., 9, 382, 1981.
270. Haynes, Jr., R. C., and Murad, F., Agents affecting calcification: Calcium parathyroid hormone, calcitonin, vitamin D and other compounds, in Goodman and Gilman's The Pharmacological Basis of Theraputics. Gilman, A. G., Ed., 1529, 1985.
271. Aroli, L. V., Calcitonin therapy in bone diseases and hypercalcemia, Arch. Intern. Med., 142, 2076, 1982.
272. Wisneski, L. A., Clinical management of postmenopausal osteoporosis, South Med. J., 85, 832, 1992.
273. Christianson, C., Prevention and treatment of osteoporosis: A review of current modalities, Bone, 13 (suppl.), 535, 1992.
274. Bisson, R., Morandi, A., and Vecchini, L., Synthetic salmon calcitonin treatment of choice in Sudeck's atropy disease, Minerva Med., 63, 1065, 1982.
275. Beveride, T., Pharmacokinetic study with synthetic salmon calcitonin, Z. Gastroenterol., 10, 12, 1976.
276. Morimoto, K., Iwakura, Y., Nakatani, E., Miyazaki, M., and Tojima, H., Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats, J. Pharm. Pharmacol., 44, 216, 1992.
277. Reginster, J. Y., Albert, A., Lecart, M. P., Lambelin, P., Denis, D., Fontaine, M. A., and Franchimont, P., One-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin, Lancet, 2, 1481, 1987.
278. Reginster, J. Y. and Franchimont, P., Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection, Clin. Exp. Rheumatol., 3, 155, 1985.
279. Overgaard, K., Agnusdel, D., Hansen, M. A., Maioli, E., Christiansen, C., and Gennari, C., Dose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women, J. Clin. Endocrin. Metab., 72, 344, 1991.
280. van der Weil, H. E., Lips, P., Nauta, J., Kwakkel, G., Hazenberg, G., Netelenbus, J. C., and van der Vijgh, W. J., Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: A double blind study of the effects of intranasal calcitonin in biochemical parameters of bone turnover, J. Bone Mineral Res., 8, 1459, 1993.
281. Marshims, R. and Stevenson, J. C., Alternatives to HRT in prevention and treatment, Baillreres Clin. Rheumatol., 7, 549, 1993.
282. Thamsborg, G., Skousgaard, S. G., Daugaard, H., Schifter, S., Kollerup, G., and Sorenson, O. H., Acute effects of nasal salmon calcitonin and bone metabolism, Calcif. Tissue Int., 53, 232, 1993.
283. Reginster, J. Y., Calcitonin for prevention and treatment of osteoporosis, Am. J. Med., 95, 445, 1993.
284. Reginster, J. Y., Gaspar, S., Deroisy, R., Zegels, B., and Franchimont, P., Prevention of osteoporosis with nasal salmon calcitonin: Effect of anti-salmon calcitonin antibody formation, Osteoporos. Int., 3, 261, 1993.
285. Reginster, J. Y., Calcitonins: Newer routes of delivery, Osteoporos. Int., 3 (suppl 2), 53, 1993.
286. New pharmaceuticals, American Druggist, October, 67, 1995.
287. Perez, A. M., Garcia, B. F. J., Calabozo, M., Benitez, C. P., Pedrosa, F. M., Crisostomo, F. C., Lopez, G. A., Perez, G. S., Ramos, M. R., and Tevar, P. J., Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established post-menopausal osteoporosis, An. Med. Interna., 12, 12, 1995.
288. Reginster, J. Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Lonueville, M., and Franchimont, P., A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss, Am. J. Med., 98, 452, 1995.
289. Luboshitzky, R. and Bar-Shalom, R., Calcitonin nasal spray for Paget's disease of the bone, Harefuah, 128, 358, 1995.
290. Pontiroli, A. E., Alberetto, M., Calderara, A., Pajetta, E., and Pozza, G., Nasal administration of glucagon and human calcitonin to healthy subjects: A comparison of powders and spray solutions and of different enhancing agents, Eur. J. Clin. Pharmacol., 37, 427, 1989.
291. Pontiroli, A. E., Intranasal administration of calcitonin and other peptides: Studies with different promoters, J. Contr. Rel., 13, 247, 1990.
292. Pontiroli, A. E., Alberetto, M., and Pozza, G., Intranasal calcitonin and plasma calcium concentrations in normal subjects, Br. Med. J., 290, 1390, 1985.
293. McSheehy, P. M., Farina, C., Airaghi, R., Allievi, E., Banfi, S., Bertolini, D., Ferni, G., Frattola, D., Oneta, S., and Pinza, M., Pharmacological evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: Comparison with salmon calcitonin and elcatonin, Bone, 16, 435, 1995.
294. Pisati, P., Feietti, F., De Bernardi, M., Tripodi, A. S., Contos, S., Germogli, R., Molleni, R., and Covini, D., Intranasal absorption of various calcitonin spray preparations, Boll. Chim. Farm., 131, 120, 1992.
295. Braga, P. C., Pratti, G., Dal Sasso, M., and Bernini, A., The effects of calcitonin nasal preparations and their excipients on mucociliary clearance in an ex-vivo frog palate test, J. Pharm. Pharmacol., 44, 938, 1992.
296. Hayakawa, E., Yamamoto, A., Shoji, Y., and Lee, V. H. L., Effect of sodium glyconate and polyoxyethylene-9-lauryl ether on the hydrolysis of varying concentrations of insulin in the nasal homogenate of the albino rabbit, Life Sci., 45, 165, 1988.
297. Brange, J., Hansen, J. F., Langkjaer, L., Markussen, J., Ribel, U., and Sorenson, R., Insulin analogs with improved absorption and characteristics, Horm. Metab. Res. Suppl., 26, 125, 1992.
298. Sanchez, A., Ygartua, P., and Fos, D., Role of surfactants in the bioavailabuity of intranasal insulin, Eur. J. Drug Metab. Pharmacokin., Spec. #3, 120, 1991.
299. Drejer, K., Vaag, A., Bech, K., Hansen, P., Sorensen, A. R., and Mygind, N., Intranasal administration of insulin with phospholipids as absorption enhancers: Pharmacokinetics in normal subjects, Diabet. Med., 9, 335, 1992.
300. Mishima, M., Wakita, Y., and Nakano, M., Studies on the promoting effects of medium chain fatty acid salts on the nasal absorption of insulin in rats, J. Pharmacodyn., 10, 624, 1987.
301. Carstens, S., Danielsen, G., Goldhammer, B., and Frederickson, O., Transport of insulin across rabbit nasal mucosa in vitro induced by didecanoly-L-α-phosphatidylcholine, Diabetes, 42, 1032, 1993.
302. Tegamnuay, P. and Mitra, A. K., Bile salt fatty acid mixed micelles as nasal absorption promoters of peptides, II. In vitro nasal absorption of insulin in rats and effects of mixed micelles on the morphological integrity of the nasal mucosa, Pharm. Res., 12, 7, 370, 1990.
303. Maitani, Y., Asano, S., Takahashi, S., Nakagaki, M., and Nagai, T., Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits, Chem. Pharm. Bull., 40, 1569, 1992.
304. Junginger, H. E., Bioadhesive polymer systems for peptide delivery, Acta Pharm. Tech., 36, 110, 1990.
305. Ryden, L. and Edman, P., Effect of polymers and microspheres on the nasal absorption of insulin in rats, Int. J. Pharm., 83, 1, 1992.
306. Morishita, M., Morishita, J., Takayomo, K., Machida, Y., and Nagai, T., Novel oral microspheres of insulin with protease inhibitor protecting from enzymatic degradation, Int. J. Pharm., 78, 1, 1992.
307. Illum, L., Jorgensen, H., Bisgaard, H., Krogsgaard, O., and Rossing, N., Bioadhesive microspheres as a potential nasal drug delivery system, Int. J. Pharm., 39, 189, 1987.
308. Bjork, E. and Edman, P., Degradable starch microspheres as a nasal delivery system for insulin, Int. J. Pharm., 49, 233, 1988.
309. Bjork, E. and Edman, P., Characterization of degradable starch microspheres as a nasal delivery system for drugs, Int. J. Pharm., 62, 187, 1990.
310. Bjork, E., Bjurstrom, S., and Edman, P., Morphological examination of rabbit nasal mucosa after nasal administration of degradable starch microspheres, Int. J. Pharm., 75, 73, 1991.
311. Farraj, N. F., Johansen, B. R., Davis, S. S., and Illum, L., Nasal administration of insulin using bioadhesive microspheres as a delivery system, J. Contr. Rel., 13, 253, 1990.
312. Edman, P., Bjork, E., and Ryden, L., Microspheres as nasal delivery system for peptide drugs, J. Contr. Rel., 21, 165, 1992.
313. Illum, L., Farraj, N. E, Fisher, A. N., Gill, I., Miglietta, M., and Benedetti, L. M., Hyaluronic acid ester microspheres as a nasal delivery system for insulin, J. Contr. Rel., 29, 133, 1994.
314. Illum, L., Farraj, N. F., and Davis, S. S., Chitosan as a novel nasal delivery system for peptide drugs, Pharm. Res., 11, 1186, 1994.
315. Illum, L. and Davis, S. S., Intranasal insulin: Clinical pharmacokinetics, Clin. Pharmacokin., 23, 30, 1992.
316. Coates, P. A., Ismail, I. S., Luzio, S. D., Griffiths, I., Ollerton, R. L., Volund, A., and Owens, D. R., Intranasal insulin: The effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects, Diabet. Med., 12, 235, 1995.
317. Schiller, P. W. and Nguyen, T. M., Activity profiles of novel side-chain to side-chain cyclized opioid peptide analogs, Neuropeptides, 5, 165, 1984.
318. Schiller, P. W., Nguyen, T. M., Maziak, L., and Lemieux, C., Structure-activity relationships of cyclic opioid analogs containing a phenylalanine residue in the 3-position, J. Med. Chem., 30, 2094, 1987.
319. 5] enkephalin with delta receptor selectivity, J. Med. Chem., 35, 2384, 1992.
320. Morimoto, K., Miyazaki, M., and Kakemi, M., Effects of proteolytic enzyme inhibitors on nasal absorption of salmon calcitonin in rats, Int. J. Pharm., 113, 1, 1995.
321. Schipper, N. G., Verhoef, J. C., Romeijn, S. G., and Merkus, F. W., Methylated beta-cyclodextrins are able to improve the nasal absorption of salmon calcitonin, Calcif. Tissue Int., 56, 280, 1995.
322. Irwin, W. J., Holbrook, P. A., and Dey, M. J., The stability of peptides in nasal enzymic systems, Int. J. Pharm., 113, 25, 1995.
323. Jorgensen, L., Larsen, R., Catherpermal, S., and Bechgaard, E., Intranasal absorption of different aqueous formulations of angiopeptin: In vivo bioavailability study, Int. J. Pharm., 113, 83, 1995.